Table 1 SARS-CoV-2 entry-related gene expressions in the lower airways and their correlations with baseline parameters in asthmatics
From: Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma
|  | Sputum (n = 104) | Bronchial brushing (n = 103) | Bronchial biopsy (n = 81) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Parameters | ACE2†| TMPRSS2†| FURIN†| ACE2†| TMPRSS2†| FURIN†| ACE2†| TMPRSS2†| FURIN†|
Age (years) | 0.009 (− 0.005 to 0.024) | − 0.012 (− 0.025 to 0.002) | 0.009 (− 0.005 to 0.023) | − 0.006 (− 0.018 to 0.007) | -0.0005 (− 0.014 to 0.013) | 0.002 (− 0.012 to 0.016) | 0.003 (− 0.012 to 0.019) | 0.012 (− 0.005 to 0.028) | 0.088 (− 0.012 to 0.016) |
Male (vs. female) | 0.320 (− 0.078 to 0.718) | 0.194 (− 0.186 to 0.575) | − 0.263 (− 0.637 to 0.112) | − 0.183 (− 0.537 to 0.170) | 0.350 (− 0.018 to 0.719) | 0.533 (0.143 to 0.924)** | 0.086 (− 0.328 to 0.500) | 0.281 (− 0.156 to 0.718) | 0.183 (− 0.258 to 0.624) |
Ever smoking (vs. never) | − 0.077 (− 0.485 to 0.332) | 0.233 (− 0.153 to 0.618) | 0.104 (− 0.279 to 0.487) | 0.252 (− 0.129 to 0.632) | 0.191 (− 0.212 to 0.594) | 0.225 (− 0.210 to 0.659) | 0.482 (0.031 to 0.933)* | 0.218 (− 0.274 to 0.710) | 0.225 (− 0.210 to 0.659) |
BMI (kg/m2) | 0.009 (− 0.029 to 0.048) | 0.024 (− 0.012 to 0.060) | 0.013 (− 0.023 to 0.049) | 0.013 (− 0.016 to 0.043) | 0.034 (0.003 to 0.064)* | − 0.014 (− 0.048 to 0.019) | − 0.035 (− 0.070 to 0.00001) | 0.004 (− 0.035 to 0.042) | − 0.014 (− 0.048 to 0.019) |
Sputum eosinophils (%)†| 0.0001 (− 0.056 to 0.056) | 0.031 (− 0.065 to 0.126) | − 0.080 (− 0.152 to − 0.008)* | − 0.080 (− 0.202 to 0.041), n = 24 | − 0.102 (− 0.236 to 0.033), n = 24 | 0.033 (− 0.153 to 0.219), n = 24 | − 0.053 (− 0.235 to 0.130), n = 27 | − 0.009 (− 0.216 to 0.197), n = 27 | − 0.030 (− 0.206 to 0.146), n = 27 |
Sputum neutrophils (%)†| 0.103 (− 0.061 to 0.267) | 0.001 (− 0.263 to 0.264) | 0.613 (0.438 to 0.788)*** | − 0.248 (− 0.674 to 0.179), n = 24 | − 0.029 (− 0.467 to 0.408), n = 24 | 0.159 (− 0.388 to 0.706), n = 24 | 0.096 (− 0.592 to 0.784), n = 27 | − 0.293 (− 1.098 to 0.512), n = 27 | 0.040 (− 0.629 to 0.709), n = 27 |
Blood eosinophils (%)†| 0.166 (0.041 to 0.291)* | 0.072 (− 0.134 to 0.278) | − 0.009 (− 0.176 to 0.157) | − 0.057 (− 0.183 to 0.068) | 0.015 (− 0.113 to 0.143) | 0.121 (− 0.032 to 0.274) | − 0.018 (− 0.159 to 0.124) | 0.010 (− 0.172 to 0.192) | − 0.011 (− 0.184 to 0.163) |
Blood neutrophils (%)†| 0.300 (0.071 to 0.529)* | − 0.307 (− 0.678 to 0.063) | 0.389 (0.095 to 0.682)* | 0.176 (− 0.027 to 0.380) | 0.090 (− 0.120 to 0.300) | 0.266 (0.014 to 0.519)* | 0.179 (− 0.059 to 0.418) | 0.398 (0.099 to 0.697)* | 0.140 (− 0.160 to 0.440) |
FeNO (ppb) | 0.001 (− 0.005 to 0.006) | 0.001 (− 0.004 to 0.007) | − 0.003 (− 0.008 to 0.002) | 0.004 (− 0.002 to 0.010) | 0.004 (− 0.002 to 0.011) | 0.0002 (− 0.007 to 0.007) | − 0.001 (− 0.008 to 0.007) | − 0.005 (− 0.013 to 0.003) | 0.0002 (− 0.007 to 0.007) |
Serum periostin (ng/ml) | 0.005 (− 0.008 to 0.018) | − 0.004 (− 0.016 to 0.009) | 0.004 (− 0.008 to 0.018) | − 0.007 (− 0.021 to 0.008) | − 0.007 (− 0.223 to 0.009) | 0.009 (− 0.007 to 0.025) | 0.003 (− 0.015 to 0.022) | − 0.010 (− 0.030 to 0.010) | 0.009 (− 0.007 to 0.025) |
Atopy (vs. no) | 0.010 (− 0.471 to 0.491) | 0.254 (− 0.202 to 0.711) | − 0.312 (− 0.761 to 0.137) | 0.276 (− 0.146 to 0.699) | 0.061 (− 0.390 to 0.512) | − 0.013 (− 0.501 to 0.475) | 0.345 (− 0.132 to 0.821) | − 0.383 (− 0.890 to 0.123) | − 0.013 (− 0.501 to 0.475) |
Post− BD FEV1 (% predicted) | − 0.011 (− 0.019 to − 0.003)** | 0.007 (− 0.001 to 0.015) | − 0.011 (− 0.019 to − 0.004)** | 0.006 (− 0.002 to 0.014) | − 0.002 (− 0.010 to 0.007) | − 0.009 (− 0.018 to 0.0004) | − 0.006 (− 0.016 to 0.005) | − 0.007 (− 0.018 to 0.004) | − 0.009 (− 0.018 to 0.0004) |
Allergic rhinitis (vs. no) | − 0.029 (− 0.440 to 0.381) | 0.069 (− 0.314 to 0.452) | − 0.239 (− 0.603 to 0.126) | − 0.007 (− 0.376 to 0.362) | − 0.245 (− 0.628 to 0.137) | − 0.287 (− 0.701 to 0.127) | − 0.040 (− 0.464 to 0.385) | − 0.218 (− 0.667 to 0.231) | − 0.287 (− 0.701 to 0.127) |
Nasal polyps (vs. no) | 0.341 (− 0.081 to 0.763) | 0.054 (− 0.352 to 0.459) | 0.228 (− 0.168 to 0.623) | − 0.293 (− 0.694 to 0.108) | 0.041 (− 0.363 to 0.446) | 0.022 (− 0.432 to 0.475) | 0.505 (0.027 to 0.982)* | 0.341 (− 0.167 to 0.849) | 0.022 (− 0.432 to 0.475) |
OCS use (vs. no) | 0.650 (0.273 to 1.027)** | 0.008 (− 0.370 to 0.387) | 0.351 (− 0.017 to 0.718) | − 0.408 (− 0.769 to − 0.047)* | 0.014 (− 0.377 to 0.404) | 0.044 (− 0.377 to 0.465) | − 0.302 (− 0.735 to 0.130) | 0.356 (− 0.104 to 0.816) | 0.044 (− 0.377 to 0.465) |
Severe asthma (vs. non− severe) | 0.882 (0.408 to 1.356)*** | − 0.008 (− 0.487 to 0.472) | 0.665 (0.210 to 1.120)** | − 0.063 (− 0.435 to 0.310) | 0.205 (− 0.186 to 0.596) | 0.005 (− 0.377 to 0.471) | 0.321 (− 0.107 to 0.749) | 0.391 (− 0.064 to 0.845) | 0.047 (− 0.377 to 0.471) |